The Baxter/Claris Warning Letter: Out Of Spec, Out Of Mind
Executive Summary
US FDA's inspection found a major problem in the operations of the facility that became Baxter’s when it acquired Claris: staff were blaming the laboratory for out-of-specification test results when they should have been fixing the manufacturing process. The result: a warning letter packed with assignments for the new owners.
You may also be interested in...
The Next New Thing In FDA Inspections: Poor Root Cause Investigations
Data integrity failures are so yesterday. Now it’s all about poor investigations into out-of-specification results.
FDA Warns Apotex Management To Demand Quality, Meet Specs
Apotex warning letter reflects FDA’s emphasis on company-wide quality systems and invalidated OOS results.
Pharma Pursues Generic Injectables Quality Turnaround Opportunities
Pfizer’s plan to acquire Hospira is part of a turnaround trend in which Big Pharma hopes its quality will rub off on the troubled generics injectables sector. The question is: Will it work?